From Bench to Bedside: Clinical Translation of Electrochemical Biosensors for Viral Diagnostics

Electrochemical biosensors have emerged as promising platforms for rapid viral diagnostics, offering high analytical sensitivity, portability, short detection times, and potential compatibility with point-of-care testing. Advances in electrode nanostructuring, biorecognition strategies, signal amplification, and miniaturized instrumentation have enabled remarkably low limits of detection, reaching femtomolar and attomolar concentrations for synthetic viral targets under optimized experimental conditions. However, exceptional analytical performance under controlled conditions does not necessarily translate into clinical diagnostic utility. This review examines the progression of electrochemical biosensors from analytical proof-of-concept toward clinical application, emphasizing the evidence required for successful translation. Following a brief overview of viral targets, recognition strategies, and electrochemical detection approaches, particular attention is given to studies evaluating authentic clinical specimens, including those targeting SARS-CoV-2, dengue virus, human papillomavirus, and hepatitis C virus. Despite encouraging findings, clinical validation remains limited by small sample sizes, incomplete reporting of diagnostic sensitivity and specificity, and insufficient multicentre evaluation, while many platforms have been assessed only using artificial or spiked matrices. Additional challenges include matrix interference, biofouling, reproducibility, sample preparation, manufacturing consistency, stability, workflow integration, and regulatory requirements. Importantly, analytical limits of detection must be interpreted in relation to viral biology, specimen characteristics, clinically relevant thresholds, and intended clinical use. Future research should prioritize reproducible sample-to-answer performance over increasingly extreme analytical sensitivity. Accordingly, this review proposes a staged translational framework encompassing native-matrix analytical validation, adequately powered clinical studies, multicentre reproducibility, manufacturing and usability assessments, and regulatory evaluation. Ultimately, the clinical adoption of electrochemical biosensors will depend on robust evidence demonstrating reliable diagnostic performance in real-world healthcare settings.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-19
DOI
https://doi.org/10.3390/diagnostics16223873
Primary Topic
Electrochemical sensors and biosensors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Bench to Bedside: Clinical Translation of Electrochemical Biosensors for Viral Diagnostics

Hashim R. Felemban, Thamir A. Alandijany
Diagnostics
Electrochemical sensors and biosensors
article

From Bench to Bedside: Clinical Translation of Electrochemical Biosensors for Viral Diagnostics

Hashim R. Felemban, Thamir A. Alandijany
article en

Abstract

Electrochemical biosensors have emerged as promising platforms for rapid viral diagnostics, offering high analytical sensitivity, portability, short detection times, and potential compatibility with point-of-care testing. Advances in electrode nanostructuring, biorecognition strategies, signal amplification, and miniaturized instrumentation have enabled remarkably low limits of detection, reaching femtomolar and attomolar concentrations for synthetic viral targets under optimized experimental conditions. However, exceptional analytical performance under controlled conditions does not necessarily translate into clinical diagnostic utility. This review examines the progression of electrochemical biosensors from analytical proof-of-concept toward clinical application, emphasizing the evidence required for successful translation. Following a brief overview of viral targets, recognition strategies, and electrochemical detection approaches, particular attention is given to studies evaluating authentic clinical specimens, including those targeting SARS-CoV-2, dengue virus, human papillomavirus, and hepatitis C virus. Despite encouraging findings, clinical validation remains limited by small sample sizes, incomplete reporting of diagnostic sensitivity and specificity, and insufficient multicentre evaluation, while many platforms have been assessed only using artificial or spiked matrices. Additional challenges include matrix interference, biofouling, reproducibility, sample preparation, manufacturing consistency, stability, workflow integration, and regulatory requirements. Importantly, analytical limits of detection must be interpreted in relation to viral biology, specimen characteristics, clinically relevant thresholds, and intended clinical use. Future research should prioritize reproducible sample-to-answer performance over increasingly extreme analytical sensitivity. Accordingly, this review proposes a staged translational framework encompassing native-matrix analytical validation, adequately powered clinical studies, multicentre reproducibility, manufacturing and usability assessments, and regulatory evaluation. Ultimately, the clinical adoption of electrochemical biosensors will depend on robust evidence demonstrating reliable diagnostic performance in real-world healthcare settings.

DiagnosticsVol. 16(22)
King Abdulaziz University (SA)
Electrochemical sensors and biosensors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon